Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 4/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | RAF1 | P04049 | 2/20 | 0.36 |
| ▸ | AOC2 | O75106 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17658800 | 0.92 | PIP5K1C (0.38) | FKBP1AGSK3BMAPK8MAPK10MAPK14 | |
| SCHEMBL17645463 | 0.90 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2EPHX1 | |
| SCHEMBL17645361 | 0.88 | TAS1R3 (0.39) | NPC1RAB9ASMN1; SMN2EPHX1 | |
| SCHEMBL28404379 | 0.85 | TACR1 (0.41) | NPC1RAB9A | |
| SCHEMBL28678330 | 0.84 | GSK3B (0.41) | FKBP1AGSK3BMAPK8MAPK10MAPK14 | |
| SCHEMBL28400919 | 0.82 | GSK3B (0.38) | FKBP1AGSK3BNPC1RAB9ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL30619319 | 0.78 | TACR1 (0.41) | — | |
| SCHEMBL22851141 | 0.78 | MAPK8 (0.36) | MAPK8MAPK10MAPK14RAF1ABL1 | |
| SCHEMBL28398406 | 0.76 | STS (0.48) | NPC1RAB9A | |
| SCHEMBL22851411 | 0.75 | FKBP1A (0.36) | FKBP1AGSK3BMAPK8MAPK10MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | NEXYS THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | NEXYS THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| EP-3902796-B1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230357260-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357260-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| CN-111196804-B | TGF-beta R1 inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-11691981-B2 | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | InventisBio Co., Ltd. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-11691981-B2 | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | InventisBio Co., Ltd. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20220054465-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3902796-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | Nexys Therapeutics, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3204377-B1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2018-09-26 | — | — | EP | disclosed |
| EP-3204377-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | Eli Lilly and Company (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617243-B2 | Aminopyridyloxypyrazole compounds | ELI LILLY AND COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| WO-2016057278-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057278-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | LILLY CO ELI (US) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | TGFBR1, TGFBR2, ACVR1 | FKBP1A 2284/4885GSK3B 344/4885MAPK8 2123/4885 |
| US-20230357260-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | TGFB1, TGFB2, TGFBR1 | FKBP1A 593/4885GSK3B 33/4885MAPK8 86/4885 |
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | ACVR1, TGFBR1, ACVRL1 | FKBP1A 1859/4885GSK3B 255/4885MAPK8 1793/4885 |
| US-20160096823-A1 | AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS | TGFBR1, TGFBR2, PDGFRB | FKBP1A 1189/4885GSK3B 253/4885MAPK8 1082/4885 |
| US-20220054465-A1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | TGFBR1, TGFBR2, ACVR1 | FKBP1A 2284/4885GSK3B 344/4885MAPK8 2123/4885 |
| US-11691981-B2 | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | TGFB1, TGFB2, TGFBR1 | FKBP1A 593/4885GSK3B 33/4885MAPK8 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.